Dan Weng

EPS Holdings, Inc. engages in the drug development business. It operates through the following segments: Contract Research Organization (CRO), Site Management Organization (SMO), Contract Sales Organization (CSO), Global Research, Ekishin, and Others. The CRO segment offers clinical trials, data management, and statistical analysis. The SMO segment enters into contracts with medical institutions to conduct clinical trials. The CSO segment provides drug information and awareness for medical and pharmaceutical industries. The Global Research segment provides consignment services through its subsidiary for multilateral clinical trials in Asia-Pacific. The Ekishin segment focuses on medical equipment, pharmaceutical and investment related businesses through its Japan and China based subsidiaries. The Others segment provides various services related to management of clinical research from business processing outsource business related to medicine and medical care. The company was founded on May 30, 1991 and is headquartered in Tokyo, Japan.

Medpace, Inc. provides clinical research services to the pharmaceutical, biotech and medical industries. It offers clinical operations, medical writing, biometrics, regulatory affairs, quality assurance, imaging core lab medical device and risk based monitoring services. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH.

EPS International Co. Ltd. a subsidiary of a public listed company EPS Co. Ltd in Tokyo, Japan, commences its business operations in April 2007. The company aims to provide a seamless clinical research and development platform through strategizing and synergizing its established research networks, valuable knowledge, know-how, resources and experiences in Asia region. The company manages large- and small-scale, global and local clinical trials covering from first-in-man to post marketing surveillance for new chemical entities, biologics and medical devices.

Part of EPS Holdings, Inc., EPS Global Research, Inc. operates clinical trials.